论文部分内容阅读
目的 为晚期非小细胞肺癌探索疗效高 ,毒性低的治疗方案。方法 3 7例晚期肺癌均经细胞学或病理学确定诊断 ,IFO 1.5 g/m2 ,静滴d1～ 5,美司那 40 0mg/次 ,分别在IFO静滴前及静滴后 4及 8小时各静滴一次 ,NVB2 5mg/m2 ,静推d1,8。每 2 1天为一周期 ,连用二周期以上评定疗效及毒性反应。结果 疗效CR3例 ( 8.1% ) ,PR2 2例 ( 5 9.5 % ) ,NC9例 ( 2 4.3 % ) ,PD3例 ( 8.1% ) ,CR +PR2 5例 ( 67.6% )。毒性反应骨髓抑制以WBC下降为最明显 10 0 % ,胃肠反应 (恶心、呕吐、便秘 )较轻。结论 IFO与NVB是治疗晚期非小细胞肺癌疗效高 ,毒性较低的治疗方案。
Objective To explore the treatment of advanced non-small cell lung cancer with high efficacy and low toxicity. Methods Thirty-seven cases of advanced lung cancer were diagnosed by cytology or pathology. IFO 1.5 g/m2, intravenous drip 1 to 5, mesna 400 mg/time, before IFO infusion and 4 and 8 hours after infusion respectively. Each intravenous infusion, NVB2 5mg/m2, static push d1,8. Every 21 days is a cycle, and more than two cycles are used to assess efficacy and toxicity. Results The efficacy of CR was 3 (8.1%), PR2 (59.5 %), NC9 (24.3%), PD (8.1%), CR+PR2 (67.6%). The toxic reaction myelosuppression was the most obvious 10% of WBC, and the gastrointestinal reactions (nausea, vomiting, constipation) were lighter. Conclusion IFO and NVB are highly effective and less toxic treatments for advanced non-small cell lung cancer.